Avid Bioservices Inc (CDMO)

[entdoc]

current cancer treatment strategy: prevention 1st. If that fails: earlier detection, and more specific targeted therapy with more sparing of normal tissue.
PPHM Bavituximab,a pilot (1st generation) anti-PS immunotherapy, makes sense because MAB Bavituximab is able to facilitate early detection of cancer (Bavi-imaging project now in clinical trials), and Bavi- has an exclusive and important docking site on the surface of cancer cells and blood vessels that feed cancer cells. It is possible that Bavi will facilitate immunizing cancer victim against recurrence of some like-cancers. Bavituximab and/or anti-PS therapy may also turn out to be a preventative for some cancers. PPHM Bavituximab development strategy does not even remotely imagine using Bavi for second-line failed cases of lung cancer, except perhaps initially. To date the safety profile of Bavi- has apparently been at the least, "satisfactory", and efficacy appears to be duplicable. PPHM appears to be moving steadily toward approval of the specific agent, and expansion of the entire anti-PS platform,of which PPHM has an exclusive.